Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Novel combinations with ruxolitinib being investigated for myelofibrosis

Abdulraheem Yacoub • 4 Jun 2021
EHA 2021
Myelofibrosis Myeloproliferative Neoplasms Fedratinib Navitoclax Parsaclisib Ruxolitinib Venetoclax

Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, discusses the approval of fedratinib and ruxolitinib, gives an overview of unmet needs in myelofibrosis and outlines novel therapies. In particular, Dr Yacoub highlights four drugs which are currently being investigated; a PI3K inhibitor called parsaclisib, the BCL2 inhibitors venetoclax and navitoclax, and a BET inhibitor, all of which are being explored in combination with ruxolitinib. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Abdulraheem Yacoub

2:06
Parsaclisib plus ruxolitinib in myelofibrosis: a promising strategy for treatment-naive patients
Abdulraheem Yacoub • 26 Aug 2022
2:42
The management of advanced phase MPNs
Abdulraheem Yacoub • 26 Aug 2022
4:15
The latest data on momelotinib for MPNs
Abdulraheem Yacoub • 10 Aug 2021
4:11
Novel therapies and combinations for myelofibrosis patients
Abdulraheem Yacoub • 10 Aug 2021

Related Videos

2:05
Donor lymphocyte infusion for relapsed myelofibrosis in the post-alloSCT setting
Alex Rampotas • 16 Apr 2024
2:52
JAK inhibitor combination therapy for the treatment of myelofibrosis
Ruben Mesa • 9 Dec 2023
1:30
XPORT-MF-034: selinexor + ruxolitinib combination therapy for MF
John Mascarenhas • 10 Dec 2023
1:38
Pelabresib plus ruxolitinib for the treatment of intermediate- and high-risk myelofibrosis
John Mascarenhas • 10 Dec 2023
The content of VJHemOnc is intended for healthcare professionals